News

Are Radiopharmaceutical Therapy Trials Designed to Undertreat?

View more

Jul 23, 2026

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

View more

Jul 22, 2026

Tau PET tracer flags early Alzheimer risk in healthy older adults

View more

Jul 21, 2026

Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing

View more

Jul 20, 2026

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer

View more

Jul 19, 2026

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

View more

Jul 16, 2026